pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-133a-1 |
Genomic Coordinates | chr18: 21825698 - 21825785 |
Synonyms | MIRN133A1, MIR133A1 |
Description | Homo sapiens miR-133a-1 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-133a-2 |
Genomic Coordinates | chr20: 62564912 - 62565013 |
Synonyms | MIRN133A2, MIR133A2 |
Description | Homo sapiens miR-133a-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-133a-3p | |||||||||||||||||||||||||||
Sequence | 53| UUUGGUCCCCUUCAACCAGCUG |74 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | FAM120C | ||||||||||||||||||||
Synonyms | CXorf17, ORF34 | ||||||||||||||||||||
Description | family with sequence similarity 120C | ||||||||||||||||||||
Transcript | NM_017848 | ||||||||||||||||||||
Other Transcripts | NM_198456 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on FAM120C | |||||||||||||||||||||
3'UTR of FAM120C (miRNA target sites are highlighted) |
>FAM120C|NM_017848|3'UTR 1 TAAGCTGAAGATGGCTTCACCAAACCAGGAAGAGGGAAAAACTTTTACTTTTCTGATTTTAGGCCCAAGCTAGAGGAGGA 81 TATAAATGCTTACCCTAGATTTCTCCAGGATTTTGGTGGGATGTCCTATTGTGTCCATCTTTTCCCCTTCCCTGCCTGTT 161 TCTGGGACTTCAGATTCAGTGGTCTGTTTCTGGAGAAGTTCTGGTCAAAGATGAATGGCAGTAAGACTAGGTCCTAGTCT 241 CAAATTGAAGATATAGCACCAATAGTTTATTTATCTCCTCTGGGAGCCTAGTAAGGCAGTAGCTGTCAGAAATTGGGTAT 321 CATCACATAAGGTCCTATAGAAAAGCTCTAGCTTTGGTTTTTCTGAGCATTTATAATGATACTCATTATCAAAGACTTAT 401 ATGATAAACCTATGAGGTTGTGGGGACAGCTGTGGCCTCCTGAGGTTTTTTTTTGTTTTTTTTTTTTCTCTATGAAGTGG 481 TATCTACCTCTTCTTCACTCCTTCCAACTTACCTACCCCTGGATTTTGTACCACCACCTCTAGCTTTGGCCTGACAATCA 561 GATAGGTAGATGTTTTCAGAAAAGTAAGGTAGTATTGGTTATTTTAATTTTTATTTTTTATTTTATACACTTCAAAAAAA 641 CTATCAATGGCCTTTGTACTGGGGGATTCAAGTGAATCAGAAAAGTACTGGGCAGATTTTTCCTGCCTCTCAACCAGTGC 721 ATTGTTTGTAAAATAGAAGATGTGGCACAGTTCATTCACTCCCTATTGCCCACACCATGAAAGGGTGGGAATCAGTGTAA 801 TGAACTTGAGTACGAAAGGGACTCAAGAGACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAATGTGT 881 GCTTGTGTGTGGGTGTGGGTGGATGTTGTGTGGGTGGGTGTATATATGAATGTGTGTATATGCATACACATACCCTTTAT 961 ATAAAGAGACAGATCTATTTATCTATACATATTTTATATATATGTAAGTGTGTGTGTATGTGTGTATATATGTGTGTATA 1041 TATATATACACACATATATACACACATACATACATACATACATACATACATACATACATGGTGATGTCCCAGAGGATTTA 1121 CTCAATTTCCCAGAAATGCTTCCACTGCTATGGAGTGGAAGGTTTCAAAAGACCACACTTTTAATCTGAAATTCTTACTA 1201 AGTCACAGTGCATTCACAACTATGAGAAGTTGGATGGGCTTCTCTAAATCAGACAAAAAGTACTTTCCAGAAATTGCCTG 1281 TTCAGAACAATAAACTCTTGGGTTGTTACAAGCTTAATCTTGAACAGAGCCCTCACATCCCATATGGTGAAAACAGGAGG 1361 TTGGAATGGGATTGGGAAGAGTTGGGCATTTCCTTATGAAGGTTTGGAGAGAAAAGGGGGGATGGGAGGTGACTACCATT 1441 TGAAAGGGCTTTCAGCCAATTTGGAGGAAATCTCTTCTGGAACTCCAGGGTCAAATTGGTTTCAGGCTAGAATTGATTGA 1521 CATGAATCCCTGAAGGAGAGAGGACTAGCTTTGGAAAGATAGGGTAGGGAAGTGTGAGGAAACTATTTGATTTTACACGC 1601 CTAGATTGTTTCATTTGTTCATTGACATTCTGACTACTGGATCTTTTCATTTGCTTTGCAAGGAAGACTTTAGAGGACTC 1681 TGGCCTGGGCCTTGAGAAGAATTCTATTAAAAGATTCTCAGCCTCCTGTGTGGCCAGGATCTGCCCAGGATAAAGAGGCT 1761 ATTCCTCCTTGCTGGAGATAATCTTGAGACAACCTTGCATTTCCAGTTTCCCTCCTTGGGCAGCCTAACTATGAGGGAGG 1841 GAAACATGGCTTGCAATAAATTAGCATTGTGTCTTCATTCAGGAATTGAGGCTTCCAGCCTCATATACCTCCTTTTGGGC 1921 TTTGTGATATTCTTGCCCAAGAAGTACCATTTCTACAGAAATACAACTGACTAATCTTCTAGCAGGGTTCTTTTTGAAAA 2001 ACCCCATGCACCTTAACCCACAGCAGGTCCTTGGTGATTTTTGCCCAGACAACCAGAAGGCTATTTGCTTACTGCCCACT 2081 TACAATGACCAGATCATAGGAAATTGAAAACAGTGTCAGACTATTTAGTCCTAATCTGTCCCAGATTAAGAGAATCCATG 2161 ATTTTCAGGGGGAGGGAGCCCTGCAATGCCTTGACCCCTGCCCAGATACTTCTTACATAAACCAAAGAAAAATGACAAGA 2241 GTGTACATCTAACCAGACAGAAGTAGAAACAAAGTATAGAAAAACCTCCTCTTTGGAATCAGCTCCCTTAATGTGGTCCC 2321 CCTTCTCTTGGACCTGCCCAACCTTTCACAACGTCTTGAAGGTAGGACTTCTATATCCAGCAAAGGAAGGGATAGTAGTA 2401 AATTTACATGGCTTGGAATTTTCTTTCTGGAGCCACAGAGGGATGAATCCTTTGGAGCTCTAAAAGCAACCAGTATCACT 2481 GAGCTGTGAGATACCTATATCTCCATTTTCTAATAGGAAGCACTTGGACTTAAAATTGCTAAGATATTTTTTGCAGTTGC 2561 TATTTCTGTGCATCTTGAATCTATCTGACACAATCAAATGACAGTATTGTTAACTCTCACACCATTAAGAAAATTTCTTA 2641 TTTTGTAGGCATTCACTGTGAGAGGTAAAATTGCTGCTTTGGCAGGTATGATTCCAGTTTGCCAAACGGCTTTTCTTCCT 2721 TCCACAACCTCTTTTTCCCCTAGCCCAGGGTGAAACAAGTGGGTCATCTCCAACCTTGATTTTTATTTGGATTCAGCATT 2801 TTGGGTTTGGAAGGTTACAAGAAGGAACCATAAATGGCCATATTCCTAGATTTTTATTTATCTGACAAAATACACAACTT 2881 AAAAGCCAGGAAAACTAAGGTTCATTACAGGGAGATGAACTTTTTCTAATTGGAGGACAAATTGTGGAAGGTGGGGTCTG 2961 ATCTTTGCTTCACCACTTGAAGAGACTGTCATCCTTCACCTGAGGTTCCATTTCTAGCTTTTATGTGACCTCTCTTGAAC 3041 AAAGTCATTTGGGAACCCCCAGAAATGACCCCTTTACATTGTAGGACCATAAGCAAAACACTGGTTGTGTATAGTCACTG 3121 ATCCCCAAGGACTTGCAGTTTTTTATTTCTGCTGGTGTGTCTTGGGATCAGCTTATAACTCCTACTCTTACTTAGTCAGT 3201 GACCAGTCCAGTCTGGTCTGGACCAGGCCTGACAAACTTCTGCTCACTTGCATCATTTTCATTCTGAGCCAGTAGGACTT 3281 TGGGTAGACTTTAAAGCCCAAGAATTGGTACTCGCTTTGGCTAGTGACATTTGATTTTTGTCTCCATCTTGATTTCTGAC 3361 ATCATTGGCCAAGTCACATTAACTTTTTTTGATCACTGAGAAAAACAGTCGAACAAGGCATTACAGAGGGTGGTTAAGGT 3441 AGAGGGTGGGGGGCAGGAATGCTTATGTAGGATAGAAAGAATGTGGGGGTAGCTGTTTGGTTATGGTGATCCAGTCCTTT 3521 GGAACCTTACAAGGCTCCTGTGGGCATGTCAATGTTACCATTACAGCCTCTACGACCCACCCACCTTTGAAAAGTCAGTA 3601 CAAGTAGACCACAGTTTAAAGTAGTTAGTATAATTCTACTAAGGTTTAATCATTATACTTGTTCACTTCCTGGTGCATAT 3681 TTCCTAAATATGCTTGGGGTGTGGGGTGGGGGGTTGAGTTTTCACTGTTCCATTGCGTGTCATCTTATATTTTTCTCCAT 3761 CCTGTGACTTTGGCATCTTACTCGACTTTCTATTTTCTTTTCCCTTGGCTTATTGCAGTAGTCTGCTGGTGCAGGTAGAG 3841 AGCTCAGTGCACCTATTCCCCTGTTACTGCTAATTATCTTGAATATTGTCAGAGGTTATTTTGATGTTCTAAGAATATAA 3921 AGTCATTTTTTACAAAATCATCTTTTCCAAGTTAAAAGCAAAATAAAAAAATCCCCTGTGCTAGGGTGCCCATTTCAGCT 4001 TTTGACATTGCCCCTGTACTTTTATAGATGCTCTTTTTGTCCGTGTTGGTAGTAACTAATGACTAGTGAATTTTCATGTA 4081 AATGAAGCAAAATAAATATTTCAGATTTTATTAATCTCTCATAACCCAGCCAAATCTGATGACTTCATTTTAATTGCTTC 4161 CCAGAAAGCACTTCCCCTCCTACCTTCTATTCTATTCTATTCTATTCTATTCTATTCTATTCTATTCTATTCTATTCTAT 4241 TCTGTTCTATTCTGTTCTATTCTGTTTTTAGAATAACACACTAGGTAAAGAAACTTTAACTGCAAGGAGTCAGTGACTTT 4321 TAGTGCTCCCTGATAAATGATGTTATTGACAAAAGTAAAAAATTATTTCATTGTTTTTTTCCTGTATTACTATCTCCTCT 4401 CCTGTGCTTTTGACAGTGTGTTTAGTGGATGGATAATATGTATTTCTCTTTCCCACTCCCAGATTCCAAATTCCCTGCCT 4481 TTTTGGCCCACCTCACCACAAAAGCTCCATAGTTTATTAATGTAAGTTTGAATGGATGCTTCTTTGGGGAAACTTCAGGA 4561 GTTAATGGAAGAGTTTCAGAAAGGAATGAGAATGCCTCAGGAGTTGTTCTGTGATGGAAATTGGTCTGTT Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Uchida Y; Chiyomaru T; Enokida H; Kawakami et al. - Urologic oncology, 2013
OBJECTIVE: We previously demonstrated that miR-133a is a tumor-suppressive microRNA (miRNA) and is commonly down-regulated in human bladder cancer (BC). The aim of this study is to determine a novel oncogenic gene targeted by miR-133a in BC. METHODS: To identify genes targeted by miR-133a, an oligo-microarray analysis was performed using the miR-133a-transfected BC cell lines. For gain/loss-of-function studies, miR-133a/si-glutathione S-transferase pi1 (GSTP1)-transfectants were subjected to XTT assay and flow cytometry to evaluate their cell viability and apoptosis status. The luciferase reporter assay was used to confirm the actual binding sites between miR-133a and GSTP1 mRNA. The mRNA and protein expression of GSTP1 in BC cell lines and clinical samples were evaluated by real-time RT-PCR and Western blot, respectively. RESULTS: MiR-133a transfection induced cell viability inhibition and apoptosis in BC cell lines. We focused on the GSTP1 gene that was the top 7 down-regulated one in the gene profile from the miR-133a-transfectants. MiR-133a transfection repressed expression levels of mRNA and protein levels of GSTP1. A luciferase reporter assay suggested that the actual binding may occur between miR-133a and GSTP1 mRNA. Cell viability inhibition and apoptosis were induced in the si-GSTP1 transfectants compared with the controls (P < 0.005). GSTP1 mRNA expression levels in 43 clinical BCs were significantly higher than those in eight normal bladder epitheliums (P = 0.0277). CONCLUSION: Our data suggest that tumor suppressive miR-133a directly regulated oncogenic GSTP1 gene in BC, and that an anti-apoptotic effect mediated by GSTP1 is maintained by miR-133a down-regulation in human BC.
LinkOut: [PMID: 21396852]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
122 hsa-miR-133a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000325 | RHOA | ras homolog family member A | 1 | 2 | ||||||||
MIRT000327 | CDC42 | cell division cycle 42 | 4 | 2 | ||||||||
MIRT000328 | ERG | ERG, ETS transcription factor | 1 | 1 | ||||||||
MIRT000329 | HCN4 | hyperpolarization activated cyclic nucleotide gated potassium channel 4 | 2 | 1 | ||||||||
MIRT000330 | UCP2 | uncoupling protein 2 | 2 | 2 | ||||||||
MIRT000331 | KRT7 | keratin 7 | 2 | 2 | ||||||||
MIRT001203 | CACNA1C | calcium voltage-gated channel subunit alpha1 C | 3 | 1 | ||||||||
MIRT001204 | HCN2 | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 | 4 | 2 | ||||||||
MIRT001816 | PKM | pyruvate kinase, muscle | 1 | 1 | ||||||||
MIRT001986 | CASP9 | caspase 9 | 3 | 3 | ||||||||
MIRT002925 | KCNQ1 | potassium voltage-gated channel subfamily Q member 1 | 4 | 1 | ||||||||
MIRT003542 | FSCN1 | fascin actin-bundling protein 1 | 5 | 4 | ||||||||
MIRT004831 | KCNH2 | potassium voltage-gated channel subfamily H member 2 | 4 | 1 | ||||||||
MIRT005604 | TAGLN2 | transgelin 2 | 5 | 4 | ||||||||
MIRT005813 | LASP1 | LIM and SH3 protein 1 | 3 | 2 | ||||||||
MIRT006571 | PNP | purine nucleoside phosphorylase | 4 | 2 | ||||||||
MIRT006680 | MSN | moesin | 2 | 1 | ||||||||
MIRT007032 | EGFR | epidermal growth factor receptor | 3 | 5 | ||||||||
MIRT007088 | VKORC1 | vitamin K epoxide reductase complex subunit 1 | 1 | 1 | ||||||||
MIRT007383 | PRDM16 | PR/SET domain 16 | 1 | 2 | ||||||||
MIRT021693 | TPM1 | tropomyosin 1 | 1 | 1 | ||||||||
MIRT021695 | FBN1 | fibrillin 1 | 1 | 1 | ||||||||
MIRT021696 | FAM120C | family with sequence similarity 120C | 1 | 1 | ||||||||
MIRT021697 | BCAN | brevican | 1 | 1 | ||||||||
MIRT021698 | TCTEX1D2 | Tctex1 domain containing 2 | 1 | 1 | ||||||||
MIRT021699 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 1 | 1 | ||||||||
MIRT021700 | RFT1 | RFT1 homolog | 1 | 1 | ||||||||
MIRT021701 | SENP1 | SUMO1/sentrin specific peptidase 1 | 1 | 1 | ||||||||
MIRT021702 | SMIM14 | small integral membrane protein 14 | 1 | 1 | ||||||||
MIRT021703 | PRELID1 | PRELI domain containing 1 | 1 | 1 | ||||||||
MIRT021704 | CNN2 | calponin 2 | 3 | 3 | ||||||||
MIRT021705 | ARPC5 | actin related protein 2/3 complex subunit 5 | 4 | 2 | ||||||||
MIRT021706 | FTL | ferritin light chain | 2 | 2 | ||||||||
MIRT021707 | CERS2 | ceramide synthase 2 | 1 | 1 | ||||||||
MIRT021708 | SEC61B | Sec61 translocon beta subunit | 1 | 1 | ||||||||
MIRT021709 | PLEKHA3 | pleckstrin homology domain containing A3 | 1 | 1 | ||||||||
MIRT021710 | EGFL7 | EGF like domain multiple 7 | 1 | 1 | ||||||||
MIRT021711 | VEGFA | vascular endothelial growth factor A | 1 | 1 | ||||||||
MIRT021712 | PIK3R2 | phosphoinositide-3-kinase regulatory subunit 2 | 1 | 1 | ||||||||
MIRT021713 | RGS3 | regulator of G protein signaling 3 | 1 | 1 | ||||||||
MIRT021714 | COL1A1 | collagen type I alpha 1 chain | 4 | 1 | ||||||||
MIRT021715 | GSTP1 | glutathione S-transferase pi 1 | 2 | 1 | ||||||||
MIRT035537 | SP1 | Sp1 transcription factor | 2 | 2 | ||||||||
MIRT035579 | KLF15 | Kruppel like factor 15 | 1 | 1 | ||||||||
MIRT045837 | NR4A2 | nuclear receptor subfamily 4 group A member 2 | 1 | 1 | ||||||||
MIRT052647 | BCL2L1 | BCL2 like 1 | 4 | 2 | ||||||||
MIRT052648 | MCL1 | MCL1, BCL2 family apoptosis regulator | 4 | 2 | ||||||||
MIRT053333 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase | 4 | 1 | ||||||||
MIRT054310 | IGF1R | insulin like growth factor 1 receptor | 3 | 2 | ||||||||
MIRT055599 | FAM160B1 | family with sequence similarity 160 member B1 | 2 | 2 | ||||||||
MIRT081957 | UBA2 | ubiquitin like modifier activating enzyme 2 | 4 | 1 | ||||||||
MIRT437400 | MMP14 | matrix metallopeptidase 14 | 3 | 1 | ||||||||
MIRT437953 | ANXA2 | annexin A2 | 4 | 1 | ||||||||
MIRT437954 | SNX30 | sorting nexin family member 30 | 4 | 1 | ||||||||
MIRT437955 | SGMS2 | sphingomyelin synthase 2 | 4 | 1 | ||||||||
MIRT438719 | PDLIM5 | PDZ and LIM domain 5 | 3 | 1 | ||||||||
MIRT452802 | PACS2 | phosphofurin acidic cluster sorting protein 2 | 2 | 2 | ||||||||
MIRT462823 | BCL3 | B-cell CLL/lymphoma 3 | 2 | 2 | ||||||||
MIRT468494 | SESN2 | sestrin 2 | 2 | 2 | ||||||||
MIRT477714 | EFHD2 | EF-hand domain family member D2 | 2 | 2 | ||||||||
MIRT483852 | EMID1 | EMI domain containing 1 | 2 | 2 | ||||||||
MIRT490039 | PRRT2 | proline rich transmembrane protein 2 | 2 | 2 | ||||||||
MIRT491349 | CDKN1A | cyclin dependent kinase inhibitor 1A | 2 | 4 | ||||||||
MIRT504443 | MC2R | melanocortin 2 receptor | 2 | 2 | ||||||||
MIRT505701 | SESN3 | sestrin 3 | 2 | 2 | ||||||||
MIRT513521 | RHOQ | ras homolog family member Q | 2 | 4 | ||||||||
MIRT517423 | HIST2H2AC | histone cluster 2 H2A family member c | 2 | 2 | ||||||||
MIRT526599 | DCAKD | dephospho-CoA kinase domain containing | 2 | 2 | ||||||||
MIRT528904 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT533060 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT534126 | SNX33 | sorting nexin 33 | 2 | 2 | ||||||||
MIRT534700 | RNF103-CHMP3 | RNF103-CHMP3 readthrough | 2 | 4 | ||||||||
MIRT535732 | MYPN | myopalladin | 2 | 2 | ||||||||
MIRT538529 | CHMP3 | charged multivesicular body protein 3 | 2 | 4 | ||||||||
MIRT550878 | IBA57 | IBA57 homolog, iron-sulfur cluster assembly | 2 | 2 | ||||||||
MIRT551260 | PSMG1 | proteasome assembly chaperone 1 | 2 | 2 | ||||||||
MIRT551981 | UGT2B10 | UDP glucuronosyltransferase family 2 member B10 | 2 | 2 | ||||||||
MIRT553866 | SYAP1 | synapse associated protein 1 | 2 | 2 | ||||||||
MIRT558810 | CDK5R1 | cyclin dependent kinase 5 regulatory subunit 1 | 2 | 2 | ||||||||
MIRT559367 | ATP13A3 | ATPase 13A3 | 2 | 2 | ||||||||
MIRT560941 | ZFP28 | ZFP28 zinc finger protein | 2 | 2 | ||||||||
MIRT565461 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 2 | 2 | ||||||||
MIRT566234 | PTMA | prothymosin, alpha | 2 | 2 | ||||||||
MIRT568217 | C11orf24 | chromosome 11 open reading frame 24 | 2 | 2 | ||||||||
MIRT608912 | NCDN | neurochondrin | 2 | 6 | ||||||||
MIRT613229 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT623563 | ITPKB | inositol-trisphosphate 3-kinase B | 2 | 2 | ||||||||
MIRT637224 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT641669 | CCNI | cyclin I | 2 | 2 | ||||||||
MIRT644440 | ALDOC | aldolase, fructose-bisphosphate C | 2 | 2 | ||||||||
MIRT644755 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT646711 | PDE1A | phosphodiesterase 1A | 2 | 2 | ||||||||
MIRT647577 | RBMXL1 | RNA binding motif protein, X-linked like 1 | 2 | 2 | ||||||||
MIRT647760 | RNF168 | ring finger protein 168 | 2 | 2 | ||||||||
MIRT649267 | C17orf64 | chromosome 17 open reading frame 64 | 2 | 2 | ||||||||
MIRT651238 | ZMAT4 | zinc finger matrin-type 4 | 2 | 2 | ||||||||
MIRT652146 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT657168 | IP6K1 | inositol hexakisphosphate kinase 1 | 2 | 2 | ||||||||
MIRT668302 | FOSL2 | FOS like 2, AP-1 transcription factor subunit | 2 | 2 | ||||||||
MIRT687546 | MLEC | malectin | 2 | 2 | ||||||||
MIRT690857 | PLEKHG2 | pleckstrin homology and RhoGEF domain containing G2 | 2 | 2 | ||||||||
MIRT697060 | PSMC4 | proteasome 26S subunit, ATPase 4 | 2 | 2 | ||||||||
MIRT699725 | SERPINH1 | serpin family H member 1 | 2 | 2 | ||||||||
MIRT700858 | PER2 | period circadian clock 2 | 2 | 2 | ||||||||
MIRT705068 | C4orf29 | abhydrolase domain containing 18 | 2 | 2 | ||||||||
MIRT709496 | ANGPT4 | angiopoietin 4 | 2 | 2 | ||||||||
MIRT713925 | PIGR | polymeric immunoglobulin receptor | 2 | 2 | ||||||||
MIRT716058 | SFTPB | surfactant protein B | 2 | 2 | ||||||||
MIRT716724 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT721677 | CMTM4 | CKLF like MARVEL transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT723379 | NFAM1 | NFAT activating protein with ITAM motif 1 | 2 | 2 | ||||||||
MIRT731340 | IGF1 | insulin like growth factor 1 | 1 | 1 | ||||||||
MIRT731591 | ZEB1 | zinc finger E-box binding homeobox 1 | 1 | 1 | ||||||||
MIRT732526 | PTBP1 | polypyrimidine tract binding protein 1 | 2 | 0 | ||||||||
MIRT732527 | KDM5C | lysine demethylase 5C | 2 | 0 | ||||||||
MIRT732589 | BCL2 | BCL2, apoptosis regulator | 2 | 0 | ||||||||
MIRT732590 | CASP3 | caspase 3 | 2 | 0 | ||||||||
MIRT733594 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 3 | 0 | ||||||||
MIRT735355 | MB | myoglobin | 1 | 0 | ||||||||
MIRT735744 | CDCA8 | cell division cycle associated 8 | 3 | 0 | ||||||||
MIRT736984 | SET | SET nuclear proto-oncogene | 1 | 0 | ||||||||
MIRT737550 | TGFB1 | transforming growth factor beta 1 | 4 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|